Prevalence and management of hyperkalemia in chronic kidney disease and heart failure patients in the Gulf Cooperation Council (GCC).

"CONFLICTS OF INTEREST AlSahow, Ali: speaker honoraria. Al‐Ghamdi, Saeed: speaker honoraria Vifor Pharma, AstraZenica and Astellas. AlJoburi, Harith: speaker honoraria AstraZeneca. AlMogbel, Osama: advisory board and speaker honoraria Vifor Pharma, AstraZeneca. Al‐Rowaie, Fadel: speaker honoraria Vifor Pharma. Attallah, Nizar: speaker honoraria Vifor Pharma. Weir, Matthew: scientific advisor AstraZeneca, Akebia, Bayer, Janssen, Boehringer‐Ingelheim, Vifor, NovoNordisk, Merck, GSK. Zannad, Faiez: personal fees for trial oversight committees, advisory boards, or speakers’ bureau from Acceleron, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer, Cardior, Cereno Scientific, Cellprothera, CVRx, G3 Pharmaceuticals, Merck, Merck AG, Novartis, NovoNordisk, Pfizer, Servier, Vifor Fresenius, and is a Co‐Founder of CardioRenal, CVCT. AbdulShafy, Mohammad; Bader, Feras; Hassan, Mohamed; Hussein, Hisham. Taha, Khaldoun: declared no conflict of interest."

"Medical writing support was provided by Walter Fürst (SFL Regulatory Affairs & Scientific Communication, Switzerland) and funded by Vifor (International) AG, Dubai, U.A.E."